Search Technologies

Three anti-HIV proteins- the antiviral lectin cyanovirin, the antiviral lectin griffithsin, and the monoclonal antibody 2G12- have been successfully expressed in the same rice seed. The co-expression allows for a low cost, stable production method for a triple anti-HIV microbicide for the prevention of HIV. The National Cancer Institute (NCI) seeks licensees for the invention microbicide and production method.

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.

The National Cancer Institute (NCI) Molecular Targets Laboratory is seeking parties interested in collaborative research to co-develop antiviral tropolone derivatives developed by systematic medicinal chemistry on the lead series.

Chimeric Antigen Receptors (CARs) are engineered proteins that can be used in a therapeutic capacity when expressed by an immune cell (e.g., a T cell). Specifically, CARs comprise a targeting domain (such as an antibody or binding fragment thereof) as well as domains that activate immune cells. By selecting a targeting domain that binds to a protein that is selectively expressed on a cancer cell, it is possible to target immune cells to the cancer cells. Upon binding to the target cell, the immune cells are activated, leading to the destruction of the cancer cell. This therapeutic approach holds great promise, as evidenced by the recent FDA-approval of CAR-T cell therapies, KYMRIAH and YESCARTA, both of which target CD19.

The National Cancer Institute seeks parties interested in co-development of safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.

The National Cancer Institute, Cancer and Inflammation Program seeks parties to co-develop inhibitors of STAT proteins for the treatment of cancer.

The National Cancer Institute, Nanobiology Program seeks parties to co-develop cancer therapeutics base on antibody fragments.

The National Cancer Institute (NCI) seeks licensing and/or co-development of an adoptive cellular therapeutic modality that targets CCR4, which is overexpressed in certain lymphoid malignancies as well as solid tumors.

The National Cancer Institute seeks parties interested to license a method to generate RNA molecules suitable for nanoparticle and biomedical applications.